Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Completed · Phase 2

Conditions studied: Castration Resistant Prostate Cancer

In brief

This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.

Key facts

Study ID
NCT01540071
Run by
Io Therapeutics
People needed
38
Starts
2011-08-01
Expected to finish
2015-12-01
Last updated by the study team
2021-05-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.